2,3-bis(palmitoyloxy)-2-propyl-N-palmitoyl-cysteinyl-seryl-seryl-asparaginyl-alanine: mitogen from E coli lipoprotein; synthetic lipopeptide; analogue of the N-terminal part of bacterial lipoprotein; constitutes a potent macrophage & B lymphocyte activator [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 135889 |
| MeSH ID | M0115354 |
| Synonym |
|---|
| 87173-03-3 |
| pam3cys-ser-ser-asn-ala |
| bppp-cssaa |
| l-alanine, n-(n2-(n-(n-(s-(2,3-bis((1-oxohexadecyl)oxy)propyl)-n-(1-oxohexadecyl)-l-cysteinyl)-l-seryl)-l-seryl)-l-asparaginyl)- |
| 2,3-bis(palmitoyloxy)propyl-n-palmitoylpentapeptide |
| 2,3-bis(palmitoyloxy)-2-propyl-n-palmitoyl-cys-ser-ser-asp-ala |
| tripalmitoyl pentapeptide |
| p3c-ssna |
| 2,3-bis(palmitoyloxy)-2-propyl-n-palmitoyl-cysteinyl-seryl-seryl-asparaginyl-alanine |
| (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoic acid |
| s-[2,3-bis(palmitoyloxy)-(2rs) propyl]-n-palmitoylcysteinyl-seryl-seryl-asparaginyl-alanine |
| mitogenic pentapeptide (pam3-cys-ser-ser-asn-ala-oh) |
| mfcd00237176 |
| s-(2,3-bis(palmitoyloxy)propyl)-n-palmitoyl-l-cysteinyl-l-seryl-l-seryl-l-asparaginyl-l-alanine |
| mitogenic pentapeptide |
| HY-148663 |
| CS-0649991 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In dose-response studies 50 micrograms Pam3Cys-Ser-(Lys)4 per mouse was the most effective dose with a long period of high antibody levels after the second booster." | ( The influence of various adjuvants on antibody synthesis following immunization with an hapten. Erhard, M; Kellner, J; Lösch, U; Schranner, I, 1992) | 0.28 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (71.43) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||